A vaccine’s ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating in hopes of generating the most effective antibodies.
Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with
October 23, 2023